Jan, 18 2019 14:33 JST

Source: Eisai

Eisai's Notification Regarding Results of Voluntary Retirement Program


TOKYO, Jan, 18 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results as follows:

1. Outline of Voluntary Retirement Program
a) Eligibility Criteria:
Employees 45 or older who have worked at Eisai for five consecutive years or more as of April 1, 2018
b) Effective Date of Retirement:
First round: March 31, 2019; Second round: March 31, 2020;
Third round: March 31, 2021
c) Number of Applicants Sought:
First round: Approximately 100*
d) Application Period:
First round: From December 11, 2018 to December 21, 2018 (may be subject to change based on the application situation). The application periods for the second and third rounds will cover a similar period of time each fiscal year.
e) Preferential Conditions:
A premium will be added to the normal retirement allowance. In addition, applicants will also have the option to receive job-placement assistance.

*The number of applicants sought for the second and third round will be determined in consideration of the outcome of the application situation.

2. Number of Confirmed Applicants / Total Amount of Premium Retirement Payments (First Round)
a) Number of Confirmed Applicants:
300 applicants
b) Total Amount of Premium Retirement Payments:
Approx. 6.6 billion yen

*Judging from the application situation, the application deadline was shortened from December 21, 2018 to December 19, 2018.

3. Impact on Financial Performance
The sum total of premium retirement payments associated with the implementation of the first round of this program will be recorded as expenses in the settlement of accounts for the third quarter of the fiscal year ending March 31, 2019. The full-year consolidated financial results forecasts for the fiscal year ending March 31, 2019 previously announced on November 1, 2018 includes a certain level for these expenses, and based on recent trends in business performance and other factors, there is no change to the full-year consolidated financial results forecasts.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
October 15 2019 20:24 JST
 
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
October 01 2019 10:46 JST
 
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
September 30 2019 11:06 JST
 
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
September 26 2019 13:21 JST
 
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
September 26 2019 13:08 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
September 24 2019 09:01 JST
 
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
September 20 2019 15:13 JST
 
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
September 20 2019 08:40 JST
 
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
September 19 2019 19:06 JST
 
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
September 18 2019 20:40 JST
 
More Press release >>

Latest Press Release


More Latest Release >>